Verheyen S, Blaton N, Kinget R, Van den Mooter G
Laboratorium voor Farmacotechnologie en Biofarmacie, K U Leuven, Campus Gasthuisberg O+N, Herestraat 49, 3000, Leuven, Belgium.
Int J Pharm. 2002 Dec 5;249(1-2):45-58. doi: 10.1016/s0378-5173(02)00532-x.
Solid dispersion literature, describing the mechanism of dissolution of drug-polyethylene glycol dispersions, still shows some gaps; (A). only few studies include experiments evaluating solid solution formation and the particle size of the drug in the dispersion particles, two factors that can have a profound effect on the dissolution. (B). Solid dispersion preparation involves a recrystallisation process (which is known to be highly sensitive to the recrystallisation conditions) of polyethylene glycol and possibly also of the drug. Therefore, it is of extreme importance that all experiments are performed on dispersion aliquots, which can be believed to be physico-chemical identical. This is not always the case. (C). Polyethylene glycol 6000 (PEG6000) crystallises forming lamellae with chains either fully extended or folded once or twice depending on the crystallisation conditions. Recently, a high resolution differential scanning calorimetry (DSC)-method, capable of evaluating qualitatively and quantitatively the polymorphic behaviour of PEG6000, has been reported. Unraveling the relationship between the polymorphic behavior of PEG6000 in a solid dispersion and the dissolution characteristics of that dispersion, is a real gain to our knowledge of solid dispersions, since this has never been thoroughly investigated. The aim of the present study was to fill up the three above mentioned gaps in solid dispersion literature. Therefore, physical mixtures and solid dispersions were prepared and in order to unravel the relationship between their physico-chemical properties and dissolution characteristics, pure drugs (diazepam, temazepam), polymer (PEG6000), solid dispersions and physical mixtures were characterised by DSC, X-ray powder diffraction (Guinier and Bragg-Brentano method), FT-IR spectroscopy, dissolution and solubility experiments and the particle size of the drug in the dispersion particles was estimated using a newly developed method. Addition of PEG6000 improves the dissolution rate of both drugs. Mechanisms involved are solubilisation and improved wetting of the drug in the polyethylene glycol rich micro-environment formed at the surface of drug crystals after dissolution of the polymer. Formulation of solid dispersions did not further improve the dissolution rate compared with physical mixtures. X-ray spectra show that both drugs are in a highly crystalline state in the solid dispersions, while no significant changes in the lattice spacings of PEG6000 indicate the absence of solid solution formation. IR spectra show the absence of a hydrogen bonding interaction between the benzodiazepines and PEG6000. Furthermore, it was concluded that the reduction of the mean drug particle size by preparing solid dispersions with PEG6000 is limited and that the influence of the polymorphic behavior of PEG6000 (as observed by DSC) on the dissolution was negligible.
描述药物 - 聚乙二醇分散体溶解机制的固体分散体文献仍存在一些空白;(A). 仅有少数研究包含评估固溶体形成以及分散颗粒中药物粒径的实验,这两个因素对溶解可能会产生深远影响。(B). 固体分散体制备涉及聚乙二醇以及可能还有药物的重结晶过程(已知该过程对重结晶条件高度敏感)。因此,对所有实验都使用可以认为在物理化学性质上相同的分散体等分试样来进行极为重要。但实际情况并非总是如此。(C). 聚乙二醇6000(PEG6000)结晶形成片晶,其链根据结晶条件要么完全伸展,要么折叠一次或两次。最近,一种能够定性和定量评估PEG6000多晶型行为的高分辨率差示扫描量热法(DSC)已被报道。阐明PEG6000在固体分散体中的多晶型行为与该分散体溶解特性之间的关系,对于我们了解固体分散体是一项实实在在的收获,因为此前从未对此进行过深入研究。本研究的目的是填补固体分散体文献中上述三个空白。因此,制备了物理混合物和固体分散体,为了阐明它们的物理化学性质与溶解特性之间的关系,通过DSC、X射线粉末衍射(吉尼尔法和布拉格 - 布伦塔诺法)、傅里叶变换红外光谱、溶解和溶解度实验对纯药物(地西泮、替马西泮)、聚合物(PEG6000)、固体分散体和物理混合物进行了表征,并使用一种新开发的方法估算了分散颗粒中药物的粒径。添加PEG6000提高了两种药物的溶解速率。涉及的机制是聚合物溶解后在药物晶体表面形成的富含聚乙二醇的微环境中药物的增溶和润湿性改善。与物理混合物相比,固体分散体的制剂并未进一步提高溶解速率。X射线光谱表明,两种药物在固体分散体中处于高度结晶状态,而PEG6000晶格间距没有显著变化表明不存在固溶体形成。红外光谱表明苯二氮䓬类药物与PEG6000之间不存在氢键相互作用。此外,得出的结论是,通过用PEG6000制备固体分散体来降低药物平均粒径的作用有限,并且PEG6000的多晶型行为(如通过DSC观察到的)对溶解的影响可以忽略不计。